

What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Analyses of data from the Phase III KEYNOTE-522 trial evaluating neoadjuvant pembrolizumab versus placebo, with chemotherapy, followed by adjuvant pembrolizumab versus placebo for localized triple-negative breast cancer (TNBC) reported a statistically significant and clinically meaningful improvement in which endpoint with the pembrolizumab regimen?**
 - Median event-free survival
 - Median overall survival
 - Both a and b
 - Neither a nor b
- Interim analysis of the MORPHEUS-Pan BC study reported encouraging activity with the combination of sacituzumab govitecan and atezolizumab in which line of therapy for patients with PD-L1-positive locally advanced or metastatic TNBC?**
 - First line
 - Second line
 - Late line
- Patritumab deruxtecan targets which of the following antigens?**
 - B7-H3
 - HER2
 - HER3
 - TROP2
- The ongoing Phase III ASCENT-05 trial is evaluating sacituzumab govitecan in combination with pembrolizumab for patients with TNBC in which of the following settings?**
 - As adjuvant therapy for patients with residual disease after neoadjuvant chemotherapy
 - As first-line therapy for patients with metastatic disease
 - As second-line therapy for patients with metastatic disease
- Sacituzumab tirumotecan targets which of the following antigens?**
 - B7-H3
 - HER2
 - HER3
 - TROP2